OCTOBER 15, 2024 MAQUI BERRY

What are Maqui berries ? It is not a common berry that individuals discuss. Maqui berry (Aristotelia chilensis) is an exotic, dark-purple fruit that grows wild in South America. Maqui berry is characterized by antioxidant and anti-inflammatory properties. The aim of this study was to evaluate the effect of maqui berry extracts on human skin fibroblasts (NHSFs) exposed to ultraviolet radiation (UVB). The photoprotective properties of the extracts were investigated via the determination of the total polyphenolic content (TPC) and antioxidant capacity

Due to its high antioxidant potential it is considered a superfruit “ It has potential health benefits, including reduced inflammation, blood sugar control and heart health All antioxidant reduce your risk f chronic diseases “ Maqui berries are reportedly packed with up to three times more antioxidants than blackberries, blueberries, strawberries and raspberries

All berries contain anthocyanins Maqui berry is rich in anthocyanins, potent antioxidants that have been linked to a healthier heart. .

The Nurses Health Study in 93,600 young and middle-aged women found that diets highest in anthocyanins were associated with a 32% reduced risk of heart attacks, compared to those lowest in these antioxidants

R recently read a report in Life Extenson magazine about using the maqui berry for treatment of dry eye syndrome. I usually rescribe gluthathione ( another powerful antioxidant) for dry eyes. The best remedy I use for dry eye syndrome is low dose naltrexne ( LDN) 1.0 mg to 4.5 mg. A recent pilot study found that this berry takn orally provided a 72 % improvement in dry eye syndrome It also increased tear production by 89 This was encouraging as most medical doctors do ot how to treat dry eye syndrome In the article i Life Extension magazine it was a small study of 13 patients getting 30 mg or 60 mg of extract daily for 2 months. I couldn’t find other pilot studies. Life Extension is known for always keeping the public informed on such good data

Until tomorrow…